Clover Biopharmaceuticals’ bid to help vaccinate the world against COVID-19 has taken a big step forward. Adjuvanted protein vaccine SCB-2019 held up against a range of variants in a phase 2/3 trial, teeing Clover up to seek approval of the relatively stable jab and deliver it to the COVAX Facility.
The clinical trial enrolled 30,000 people on four continents to receive the Clover vaccine or placebo. Against all variants, vaccine efficacy clocked in at 67%. Efficacy against moderate-to-severe COVID-19 was 84%, and efficacy against severe COVID-19 and hospitalization was 100%.
